Uma visão geral sobre as complicações cardiovasculares associadas à COVID-19: revisão de literatura
An overview of cardiovascular complications associated with COVID-19: literature review
DOI:
https://doi.org/10.34119/bjhrv5n5-165Keywords:
Coronavírus, cardiopatias, síndrome respiratória aguda graveAbstract
A COVID-19 é uma doença que surgiu no final do ano de 2019, na China, e rapidamente disseminou por outros países, causando uma pandemia a nível mundial. As manifestações da COVID-19 incluem principalmente, problemas respiratórios, mas também pode causar complicações graves em diversos outros órgãos. Complicações cardiovasculares são comuns e afetam, majoritariamente, indivíduos com cardiopatias prévias. O objetivo desta revisão foi fornecer evidências com uma visão geral sobre as complicações cardiovasculares associadas à COVID-19. Trata-se de uma revisão integrativa da literatura, com estudos publicados de janeiro de 2020 a dezembro de 2021. Foram considerados artigos completos publicados em revistas indexadas disponíveis nas bases de dados online como Scientific Electronic Library Online (SCIELO), Pubmed e Google Scholar. Identificamos que a lesão miocárdica e miocardite, infarto agudo do miocárdio, insuficiência cardíaca aguda e cardiomiopatia, disritmias e evento tromboembólico venoso são as principais complicações cardiovasculares associadas à COVID-19. Essas complicações podem significar o risco vital grave para pacientes com COVID-19 e é importante que profissionais emergencistas estejam cientes para tratá-las.
References
Kilianski A, Mielech AM, Deng X, Baker SC. Assessing Activity and Inhibition of Middle East Respiratory Syndrome Coronavirus Papain-Like and 3C-Like Proteases Using Luciferase-Based Biosensors. J Virol. 2013;87(21):11955–62.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020;1–9.
National Health Commission of People’s Republic of China. Prevent guideline of 2019-nCoV [Internet]. National Health Commission of People’s Republic of China. 2020 [cited 2020 Mar 24]. p. 1. Available from: http://www.nhc.gov.cn/xcs/yqfkdt/202001/bc661e49b5bc487dba182f5c49ac445b.shtml
Center for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) [Internet]. Center for Disease Control and Prevention. 2020 [cited 2020 Mar 24]. p. 1. Available from: https://www.cdc.gov/coronavirus/2019-nCoV/summary.html
Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. Viruses. 2020;12(2):1–8.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
Lipsitch M, Cohen T, Cooper B, Robins JM, Ma S, James L, et al. Transmission Dynamics and Control of Severe Acute Respiratory Syndrome. J Invest Dermatol. 2003 Feb;300(5627):1966–1970.
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun [Internet]. 2020 May;109:102433. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0896841120300469
Behzad S, Aghaghazvini L, Radmard AR, Gholamrezanezhad A. Extrapulmonary manifestations of COVID-19: Radiologic and clinical overview. Clin Imaging [Internet]. 2020 Oct;66:35–41. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0899707120301674
Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy [Internet]. 2020 Jul 27;75(7):1730–41. Available from: https://onlinelibrary.wiley.com/doi/10.1111/all.14238
WHO. World Health Organization. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19) [Internet]. World Health Organization (WHO). 2020 [cited 2022 Feb 18]. p. 1. Available from: http://who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
Medical expert group of Tongji hospital. Quick guide to the diagnosis and treatment of pneumonia for novel coronavirus infections (third edition) [Internet]. Herald Med. 2020 [cited 2020 Mar 24]. p. 1. Available from: http://kns.cnki.net/kcms/detail/42.1293.r.20200130.1803.002.html
Wang C, Wang X. Prevalence, nosocomial infection and psychological prevention of novel coronavirus infection. Chin Gen Pr Nurs. 2020;18(1):2–3.
Magadum A, Kishore R. Cardiovascular Manifestations of COVID-19 Infection. Cells [Internet]. 2020 Nov 19;9(11):2508. Available from: https://www.mdpi.com/2073-4409/9/11/2508
Azevedo RB, Botelho BG, Hollanda JVG de, Ferreira LVL, Junqueira de Andrade LZ, Oei SSML, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens [Internet]. 2021 Jan 27;35(1):4–11. Available from: http://www.nature.com/articles/s41371-020-0387-4
Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr Clin Res Rev [Internet]. 2020 May;14(3):247–50. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1871402120300539
Saleh K Bin, Hafiz A, Alsulaiman K, Aljuhani O, Alharbi S, Alharbi A, et al. Clinical characteristics and outcomes of patients with heart failure admitted to the intensive care unit with coronavirus disease 2019 (COVID-19): A multicenter cohort study. Am Hear J Plus Cardiol Res Pract [Internet]. 2021 Jul;7(January):100033. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2666602221000318
Bois MC, Boire NA, Layman AJ, Aubry MC, Alexander MP, Roden AC, et al. COVID-19-Associated Nonocclusive Fibrin Microthrombi in the Heart. Circulation. 2021;2:230–43.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. 2020;1–9.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet [Internet]. 2020 Mar;395(10229):1054–62. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673620305663
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID ‑ 19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med [Internet]. 2020; Available from: https://doi.org/10.1007/s00134-020-05991-x
CDC. Centro de Controle e Prevenção de Doenças do Coronavírus 2019 (COVID-19) [Internet]. 2020 [cited 2020 Dec 18]. p. 1. Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 2020;(January).
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 ( COVID-19 ) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. 2020;2019.
Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, Goor H Van. Tissue distribution of ACE2 protein , the functional receptor for SARS coronavirus . A first step in understanding SARS pathogenesis. 2004;631–7.
Zhou P, Yang X, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Internet]. 2020 Mar 12;579(7798):270–3. Available from: http://www.nature.com/articles/s41586-020-2012-7
Ge X, Li J, Yang X, Chmura AA, Zhu G, Epstein JH, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature [Internet]. 2013;503(7477):535–8. Available from: http://dx.doi.org/10.1038/nature12711
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin ‑ converting enzyme 2 ( ACE2 ) as a SARS ‑ CoV ‑ 2 receptor : molecular mechanisms and potential therapeutic target. Intensive Care Med [Internet]. 2020;46(4):586–90. Available from: https://doi.org/10.1007/s00134-020-05985-9
Libby P, Simon DI. Inflammation and Thrombosis. :1718–21.
Davis MM, Taubert K, Brown DW, Mensah GA, Baddour LM, Dunbar S, et al. AHA / ACC Science Advisory Cardiovascular Disease A Science Advisory From the American Heart Association / Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation , the. 2006;6083(71).
Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med [Internet]. 2018 Jan 25;378(4):345–53. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1702090
Chen L, Li X. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. 2020;2–5.
Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients With COVID-19. 2020;1–2.
Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID ‑ 19 in China. 2020;(0123456789).
Driggin E, Madhavan M V, Bikdeli B, Chuich T, Harm PD. Cardiovascular Considerations for Patients, Health CareWorkers, and Health Systems During the COVID-19 Pandemic. J Am Cardiol. 2020;75(18):2353–71.
Pouw N, de Maat J van, Veerman K, Oever J ten, Janssen N, Abbink E, et al. Clinical characteristics and outcomes of 952 hospitalized COVID-19 patients in the Netherlands: A retrospective cohort study. PLoS One [Internet]. 2021;16(3 March):1–15. Available from: http://dx.doi.org/10.1371/journal.pone.0248713
Luo H chun, You C yan, Lu S wei, Fu Y qiang. Characteristics of coagulation alteration in patients with COVID-19. Ann Hematol. 2021;100(1):45–52.
Badedi M, Darraj H, Alnami AQ, Makrami A, Mahfouz MS, Alhazmi K, et al. Epidemiological and clinical characteristics of deceased covid-19 patients. Int J Gen Med. 2021;14:3809–19.
Shchendrygina A, Nagel E, Puntmann VO, Valbuena-Lopez S. COVID-19 myocarditis and prospective heart failure burden. Expert Rev Cardiovasc Ther [Internet]. 2021;19(1):5–14. Available from: https://doi.org/10.1080/14779072.2021.1844005
Intensive Care National Audit & Research Centre. ICNARC report on COVID-19 in critical care. 2020. p. 1.
Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. 2020;(January):19–21.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. 2020;(January).
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. 2020;(January).
Chen T, Wu D, Chen H, Yan W, Wang T, Guo W, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;1091(December 2019):1–14.
Welt FGP, Shah PB, Aronow HD, Bortnick AE, Henry TD, Sherwood MW, et al. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic. J Am Cardiol. 2020;75(18):2372 – 5.
Corrales-medina VF, Alvarez KN, Weissfeld LA, Angus C, Chirinos JA, Chang CH, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. 2016;313(3):264–74.
Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). 2020;2019.
Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. 2020;1–8.
Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. 2020;63(3):364–74.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Nat 2020; 2020;1(1):422–420.
Liu K, Fang Y, Deng Y, Liu W, Wang M, Ma J, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. 2020;0(9):1025–31.
Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz [Internet]. 2020 May 5;45(3):230–2. Available from: http://link.springer.com/10.1007/s00059-020-04909-z
Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. 2016;(Lv):78–80.
Buzon J, Roignot O, Lemoine S, Perez P, Kimmoun A, Levy B, et al. Takotsubo Cardiomyopathy Triggered by Influenza A Virus. 2017;2017–9.
Danzi GB, Loffi M. Acute pulmonary embolism and COVID-19 pneumonia : a random association ? 2020;2020.
Xie Y, Wang X, Yang P, Zhang S. COVID-19 Complicated by Acute Pulmonary Embolism. Radiol Cardiothorac Imaging [Internet]. 2020 Apr 1;2(2):e200067. Available from: http://pubs.rsna.org/doi/10.1148/ryct.2020200067
Chen J, Wang X, Zhang S. Findings of acute pulmonary embolism in COVID-19 patients.
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. 2020;(February):844–7.
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. 2020;(March):1094–9.
Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004;59(3):252–6.
Elfik AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. 2020;(January).
Chavez S, Long B, Koyfman A, Liang SY. Coronavirus Disease (COVID-19): A primer for emergency physicians. 2020;(January).
KALETRA(R) oral film coated tablets, oral solution, lopinavir ritonavir oral film coated tablets, oral solution. Product insert. North Chicago. 2013.
Bryant CLO, Trupp RJ. Drugs That May Cause or Exacerbate Heart Failure. 2016.
Kandolf R, Lewalter T, To E. Chloroquine cardiomyopathy – a review of the literature. 2013;3973(3):434–42.
